SELLAS Life Sciences Group, Inc. (SLS) Comparison with companies in other sectors?

SELLAS Life Sciences Group, Inc. has a share price of 99.78M. You can analyze SELLAS Life Sciences Group, Inc. (SLS) competitors across different market sectors through stock heatmaps.

What are SLS's NET and operating margins?

SELLAS Life Sciences Group, Inc. (SLS) operating margin is around 0.00, and net profit margin is approximately 0.00 as of the latest reports.

In what way does SLS's earnings per share (EPS) trend reflect its financial momentum?

SELLAS Life Sciences Group, Inc. (SLS) EPS is -0.36 (If EPS value is positive, then “signals consistent profit growth” if Negative then “signals consistent loss”). This metric is also critical in assessing valuation metrics like the P/E ratio for SELLAS Life Sciences Group, Inc. is -6.04, and the company’s ability to reinvest or distribute profits.

What does a high ROE mean for SELLAS Life Sciences Group, Inc.?

A high ROE suggests efficient use of shareholder equity to generate profit. It often signals strong management and profitability.

How do I know if AAPL is overvalued or undervalued?

Check valuation ratios for SELLAS Life Sciences Group, Inc. like P/E which is -6.75, P/B which is 6.59, and PEG which is 0.08. Compare them with sector averages to evaluate if the stock is priced fairly.

SELLAS Life Sciences Group, Inc.

SLS•NASDAQ

Healthcare

Biotechnology

$2.17

$0.005(0.23%)

Fundamental Analysis of SELLAS Life Sciences Group, Inc. (SLS)

Comprehensive financial metrics and ratios analysis

EPS (TTM)

$-0.36

P/E Ratio

-6.04

ROE

-1.94%

Net Margin

Key Financial Metrices

Valuation Metrics

4 metrics

Market CapTotal market value of outstanding shares

$217.02M

Shares OutstandingTotal number of shares issued

$99.78M

Book Value/ShareNet worth per share

$0.32

Revenue/ShareAnnual revenue per share

Profitability Metrics

6 metrics

EPS (TTM)Earnings per share trailing twelve months

$-0.36

Net MarginNet income as percentage of revenue

Operating MarginOperating income as percentage of revenue

ROEReturn on shareholders' equity

-193.67%

ROAReturn on total assets

-77.61%

ROCEReturn on capital employed

-99.51%

Cash Flow Metrics

3 metrics

Free Cash Flow/ShareCash generated per share after capex

$-0.38

Cash/ShareCash and equivalents per share

$0.32

FCF YieldFree cash flow as percentage of market cap

-15.75%

Dividend Metrics

2 metrics

Dividend/ShareAnnual dividend payment per share

Dividend YieldAnnual dividend as percentage of stock price

Financial Ratios Analysis data is not available for SLSFinancial Ratios Analysis details for SLS are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Sector Benchmarking data is not available for SLSSector Benchmarking details for SLS are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Understanding Fundamental Analysis for SELLAS Life Sciences Group, Inc. Investment Decisions

What is Fundamental Analysis?

Fundamental analysis is a method used to assess the intrinsic value of SELLAS Life Sciences Group, Inc.. Using financial reports, management structure, competitive position, and market environment, investors can determine whether the stock is undervalued or overvalued. This analysis helps investors like you make more informed investment decisions, taking into account SELLAS Life Sciences Group, Inc.'s unique business strengths and challenges.

Key Financial Metrics for SELLAS Life Sciences Group, Inc.

For SELLAS Life Sciences Group, Inc., essential financial indicators include EPS -0.36, PE -6.04, and ROE -1.94. These key ratios reveal insights into SELLAS Life Sciences Group, Inc.'s profitability, valuation, and operational health. Understanding these metrics enables you to compare SELLAS Life Sciences Group, Inc. with its industry peers and decide whether it presents a viable investment opportunity.

Profitability and Operational Efficiency of SELLAS Life Sciences Group, Inc.

Metrics like Net Margin - and ROA -77.61% shed light on how well SELLAS Life Sciences Group, Inc. is generating profits. A high profitability ratio often indicates strong management and a solid business model, which are essential for long-term growth. These metrics are crucial in assessing whether SELLAS Life Sciences Group, Inc. can sustain its operations and continue growing in the future.

Valuation and Market Position of SELLAS Life Sciences Group, Inc.

Using ratios such as P/B Ratio 6.59 and PEG Ratio 0.08, investors can assess whether SELLAS Life Sciences Group, Inc. is appropriately valued based on its financials and growth potential. These figures, combined with SELLAS Life Sciences Group, Inc.'s market capitalization, give insight into its competitive positioning and investor expectations, helping you make informed decisions on pricing and value.

Financial Health and Risk Assessment for SELLAS Life Sciences Group, Inc.

Financial health indicators, such as Debt/Equity Ratio 0.03 and Cash Flow $-0.38, provide a snapshot of SELLAS Life Sciences Group, Inc.'s ability to meet financial obligations and handle economic setbacks. A company with a strong balance sheet and solid cash flow, like SELLAS Life Sciences Group, Inc., is more likely to weather financial storms, making it a safer investment.

Long-Term Investment Strategy for SELLAS Life Sciences Group, Inc.

Investing in SELLAS Life Sciences Group, Inc. based on fundamental analysis emphasizes long-term business growth rather than short-term market trends. Investors looking at SELLAS Life Sciences Group, Inc. focus on its solid financial performance, industry standing, and competitive advantages, all of which suggest sustainable growth and the potential for steady returns over time.

Fundamental Analysis FAQ

;